Dashboard
Manage Tickers

FHTXFoghorn Therapeutics Inc.

Nasdaq foghorntx.com


$ 5.89 $ 0.35 (6.22 %)    

Wednesday, 08-May-2024 15:57:32 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 5.98
$ 5.94
$ 0.00 x 0
$ 0.00 x 0
$ 5.61 - $ 5.94
$ 2.70 - $ 9.97
55,696
na
253.72M
$ 1.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-06-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-18-2021 12-31-2020 10-K
15 12-04-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Fogh...
05/07/2024 10:49:39

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...

hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Fogh...
05/01/2024 11:26:48

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...

foghorn-therapeutics-has-appointed-kristian-humer-as-chief-financial-officer
Foghorn Therapeutics Has Appointed Kristia...
04/16/2024 11:09:46

wedbush-reiterates-outperform-on-foghorn-therapeutics-maintains-13-price-target
Wedbush Reiterates Outperform on Foghorn T...
04/10/2024 12:04:19

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.

hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Fogh...
04/10/2024 10:18:33

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...

foghorn-therapeutics-presents-new-preclinical-data-on-fhd-909-says-fhd-909-demonstrated-favorable-tolerability-and-dose-dependent-single-agent-activity-in-brg1-mutated-cancers-preclinically
Foghorn Therapeutics Presents New Preclini...
04/09/2024 20:34:40

wedbush-reiterates-outperform-on-foghorn-therapeutics-maintains-13-price-target
Wedbush Reiterates Outperform on Foghorn T...
03/08/2024 15:08:58

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.

foghorn-therapeutics-q4-earnings-insights
Foghorn Therapeutics: Q4 Earnings Insights
03/07/2024 14:05:06

foghorn-therapeutics-reports-fy23-collaboration-revenue-of-342m-vs-192m-a-year-ago
Foghorn Therapeutics Reports FY23 Collabor...
03/07/2024 12:16:50

foghorn-therapeutics-to-present-new-preclinical-data-at-2024-aacr-annual-meeting-reflecting-advances-with-multiple-potential-first-in-class-medicines-including-the-selective-inhibitor-of-brm-fhd-909
Foghorn Therapeutics To Present New Precli...
03/05/2024 21:51:19

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in ...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
02/08/2024 17:31:40

why-foghorn-therapeutics-fhtx-stock-is-exploding-higher
Why Foghorn Therapeutics (FHTX) Stock Is E...
02/08/2024 16:48:28

Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for c...

Core News & Articles
Foghorn Announced That Eli Lilly Has Selec...
02/08/2024 12:13:21

. The primary target patient population is BRG1 mutated non-small cell lung cancer (NSCLC).

foghorn-therapeutics-appoints-stephen-dipalma-as-treasurer-and-interim-cfo-effective-immediately
Foghorn Therapeutics Appoints Stephen DiPa...
01/17/2024 21:12:52

-SEC Filing

foghorn-therapeutics-highlights-clinical-program-updates-research-progress-and-provides-strategic-objectives-for-2024
Foghorn Therapeutics Highlights Clinical P...
01/08/2024 13:38:39

- FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; prec...

foghorn-therapeutics-cfo-allan-reine-to-depart-to-pursue-another-opportunity
Foghorn Therapeutics CFO Allan Reine To De...
01/03/2024 21:05:50

foghorn-therapeutics-says-clinical-data-from-phase-1-study-of-fhd-286-a-novel-brg1brm-inhibitor-in-patients-with-advanced-hematologic-malignancies-to-be-presented-at-american-society-of-hematology-annual-meeting
Foghorn Therapeutics Says Clinical Data Fr...
12/01/2023 12:06:38

morgan-stanley-maintains-equal-weight-on-foghorn-therapeutics-lowers-price-target-to-6
Morgan Stanley Maintains Equal-Weight on F...
11/13/2023 14:08:39

Morgan Stanley analyst Vikram Purohit maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Equal-Weight and lowers the price ...

foghorn-therapeutics-to-present-at-upcoming-conferences-including-new-preclinical-data-from-ep300-and-cbp-selective-degrader-programs
Foghorn Therapeutics To Present At Upcomin...
10/24/2023 12:14:15

Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat...

foghorn-therapeutics-announces-clinical-data-from-phase-1-study-of-fhd-286-in-metastatic-uveal-melanoma-to-be-presented-at-esmo-congress
Foghorn Therapeutics Announces Clinical Da...
10/13/2023 12:12:00

Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION